Literature DB >> 17490649

Barrier qualities of the mouse eye to topically applied drugs.

Zhao Wang1, Chi Wai Do, Marcel Y Avila, Richard A Stone, Kenneth A Jacobson, Mortimer M Civan.   

Abstract

The mouse eye displays unusually rapid intraocular pressure (IOP) responses to topically applied drugs as measured by the invasive servo-null micropipette system (SNMS). To learn if the time course reflected rapid drug transfer across the thin mouse cornea and sclera, we monitored a different parameter, pupillary size, following topical application of droplets containing 40 microM (0.073 microg) carbachol. No miosis developed from this low carbachol concentration unless the cornea was impaled with an exploring micropipette as used in the SNMS. We also compared the mouse IOP response to several purinergic drugs, measured by the invasive SNMS and non-invasive pneumotonometry. Responses to the previously studied non-selective adenosine-receptor (AR) agonist adenosine, the A(3)-selective agonist Cl-IB-MECA and the A(3)-selective antagonist MRS 1191 were all enhanced to varying degrees, in time and magnitude, by corneal impalement. We conclude that the thin ocular coats of the mouse eye actually present a substantial barrier to drug penetration. Corneal impalement with even fine-tipped micropipettes can significantly enhance entry of topically-applied drugs into the mouse aqueous humor, reflecting either direct diffusion around the tip or a more complex impalement-triggered change in ocular barrier properties. Comparison of invasive and non-invasive measurement methods can document drug efficacy at intraocular target sites even if topical drug penetration is too slow to manifest convincing physiologic effects in intact eyes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17490649      PMCID: PMC2151915          DOI: 10.1016/j.exer.2007.03.006

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  23 in total

1.  Common actions of adenosine receptor agonists in modulating human trabecular meshwork cell transport.

Authors:  J C Fleischhauer; C H Mitchell; W D Stamer; M O Karl; K Peterson-Yantorno; M M Civan
Journal:  J Membr Biol       Date:  2003-05-15       Impact factor: 1.843

Review 2.  Number of people with glaucoma worldwide.

Authors:  H A Quigley
Journal:  Br J Ophthalmol       Date:  1996-05       Impact factor: 4.638

Review 3.  Nucleoside and nucleobase transport systems of mammalian cells.

Authors:  D A Griffith; S M Jarvis
Journal:  Biochim Biophys Acta       Date:  1996-10-29

Review 4.  Recent advances in the molecular biology of nucleoside transporters of mammalian cells.

Authors:  C E Cass; J D Young; S A Baldwin
Journal:  Biochem Cell Biol       Date:  1998       Impact factor: 3.626

5.  Adenosine stimulates Cl- channels of nonpigmented ciliary epithelial cells.

Authors:  D A Carré; C H Mitchell; K Peterson-Yantorno; M Coca-Prados; M M Civan
Journal:  Am J Physiol       Date:  1997-10

6.  A3 adenosine receptors regulate Cl- channels of nonpigmented ciliary epithelial cells.

Authors:  C H Mitchell; K Peterson-Yantorno; D A Carré; A M McGlinn; M Coca-Prados; R A Stone; M M Civan
Journal:  Am J Physiol       Date:  1999-03

7.  Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

8.  The effectiveness of intraocular pressure reduction in the treatment of normal-tension glaucoma. Collaborative Normal-Tension Glaucoma Study Group.

Authors: 
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258

9.  Functional expression of a sodium dependent nucleoside transporter on rabbit cornea: Role in corneal permeation of acyclovir and idoxuridine.

Authors:  Soumyajit Majumdar; Sriram Gunda; Ashim Mitra
Journal:  Curr Eye Res       Date:  2003 Mar-Apr       Impact factor: 2.424

10.  Carboxyfluorescein. A probe of the blood-ocular barriers with lower membrane permeability than fluorescein.

Authors:  P A Grimes; R A Stone; A M Laties; W Li
Journal:  Arch Ophthalmol       Date:  1982-04
View more
  6 in total

1.  Nucleoside-derived antagonists to A3 adenosine receptors lower mouse intraocular pressure and act across species.

Authors:  Zhao Wang; Chi Wai Do; Marcel Y Avila; Kim Peterson-Yantorno; Richard A Stone; Zhan-Guo Gao; Bhalchandra Joshi; Pedro Besada; Lak Shin Jeong; Kenneth A Jacobson; Mortimer M Civan
Journal:  Exp Eye Res       Date:  2009-10-28       Impact factor: 3.467

Review 2.  Ocular Purine Receptors as Drug Targets in the Eye.

Authors:  Kenneth A Jacobson; Mortimer M Civan
Journal:  J Ocul Pharmacol Ther       Date:  2016-08-30       Impact factor: 2.671

3.  Truncated (N)-Methanocarba Nucleosides as Partial Agonists at Mouse and Human A3 Adenosine Receptors: Affinity Enhancement by N6-(2-Phenylethyl) Substitution.

Authors:  Dilip K Tosh; Veronica Salmaso; Harsha Rao; Amelia Bitant; Courtney L Fisher; David I Lieberman; Helmut Vorbrüggen; Marc L Reitman; Oksana Gavrilova; Zhan-Guo Gao; John A Auchampach; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2020-04-09       Impact factor: 7.446

4.  Depression of intraocular pressure following inactivation of connexin43 in the nonpigmented epithelium of the ciliary body.

Authors:  Mónica R Calera; Zhao Wang; Roberto Sanchez-Olea; David L Paul; Mortimer M Civan; Daniel A Goodenough
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-01-24       Impact factor: 4.799

Review 5.  Adenosine receptors as promising targets for the management of ocular diseases.

Authors:  Eleonora Spinozzi; Cecilia Baldassarri; Laura Acquaticci; Fabio Del Bello; Mario Grifantini; Loredana Cappellacci; Petrelli Riccardo
Journal:  Med Chem Res       Date:  2021-01-25       Impact factor: 2.351

6.  Telemetric monitoring of 24 h intraocular pressure in conscious and freely moving C57BL/6J and CBA/CaJ mice.

Authors:  Ruixia Li; John H K Liu
Journal:  Mol Vis       Date:  2008-04-18       Impact factor: 2.367

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.